QuidelOrtho Corp (QDEL): R&D Expense

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2023-01-01 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$186.20M

Year ended 2025-12-28

$180.90M

Trailing 12 months to 2026-06-28

-0.3%

3-year compound annual growth

2021-01-03 R&D Expense (USD) 2025-12-28

Period ended	R&D Expense	Change YoY	Source filing
2025-12-28	$186.20M	-14.9%	2026-02-19, From 2024-12-30
2024-12-29	$218.70M	-10.7%	2026-02-19, From 2024-01-01
2023-12-31	$245.00M	+30.4%	2026-02-19, From 2023-01-02
2023-01-01, Fiscal 2022	$187.90M	n/c	2025-02-27, From 2022-01-03
2022-01-02, Fiscal 2021	$95.70M	+13.5%	2024-08-01, From 2021-01-04
2021-01-03, Fiscal 2020	$84.30M	n/a	2023-02-23, From 2019-12-30

R&D Expense at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	R&D Expense	Change YoY
QuidelOrtho Corp (QDEL)	2025-12-28	$186.20M	-14.9%
Idexx Laboratories Inc (IDXX)	2025-12-31	$251.21M	+14.3%
Lantheus Holdings, Inc. (LNTH)	2025-12-31	$177.31M	+5.5%
Neogen Corp (NEOG)	2026-05-31	$18.40M	-12.8%
Myriad Genetics Inc (MYGN)	2025-12-31	$106.80M	-5.8%
Intellia Therapeutics, Inc. (NTLA)	2025-12-31	$388.86M	-16.6%
Alpha Teknova, Inc. (TKNO)	2025-12-31	$2.20M	-20.4%
Immucell Corp (ICCC)	2025-12-31	$3.04M	-22.0%
Aspira Women's Health Inc. (AWHL)	2025-12-31	$2.88M	-11.9%

Compare QDEL, IDXX, LNTH, NEOG side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗